NDA 20-080/S-021/S-024/S-025/S-026/S-027

Glaxo Wellcome
Attention: Judith Babo
Project Director, Regulatory Affairs
Five Moore Drive
Research Triangle Park, NC 27709

2 FEB 2001

Dear Ms. Babo:

Please refer to your supplemental new drug applications dated March 11, 1997 (S-021), December 19, 1997 (S-024), December 18, 1998 (S-025), August 27, 1999 (S-026), and August 10, 2000 (S-027), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Imitrex (sumatriptan succinate) Injection.

These "Changes Being Effected" supplemental new drug applications provide for revisions to the package insert, patient package insert, and container labels. The specific changes are as follows:

S-021
The supplement provides for revisions to the **PRECAUTIONS - General** section to reflect safety database reports of ischemic colitis. Additionally, the **ADVERSE REACTIONS: Postmarketing Experience** subsection was reformatted to list events under appropriate body systems consistent with the **ADVERSE REACTIONS: Other Events Observed in Association With the Administration of IMITREX Injection** subsection.

S-024
The supplement provides for revisions to the carton, package insert, and patient package insert to aid in the proper use of the Imitrex injection prefilled syringe pack, i.e., the Imitrex STATdose System

S-025
The supplement provides for the following revisions:

1) Changed **CONTRAINDICATIONS**, **WARNINGS**, **PRECAUTIONS**, and **ADVERSE REACTIONS** to be consistent with Imitrex Tablets labeling.
2) Added a contraindication for use in patients with severe hepatic impairment.
3) Added thrombophlebitis & retinal vein thrombosis to **ADVERSE REACTIONS**: Postmarketing Experience section.

S-026
The supplement provides for the addition of a **Geriatric Use** subsection to **PRECAUTIONS**.

S-027
The supplement provides for the following revisions:

1) Added the numerals "1" and "2" to the sample and trade syringe cartridge pack labels under each of the 2 prefilled, single-dose syringe cartridge containers to help patients identify used syringes. Changed Caution statement to "Rx only." Changed "PROFESSIONAL SAMPLES—NOT FOR SALE" to "Sample—Not for Sale."

2) In patient's instructions, revised pictorial illustrations to show new syringe cartridge pack label.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted August 27, 1999/Label Code RL-650, patient package insert submitted December 18, 1998, and immediate container and carton labels submitted August 10, 2000), which incorporates all of the revisions listed. Accordingly, these supplemental applications are approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under the above supplemental applications are permitted by section 314.70(c) of the regulations to be instituted prior to approval of these supplements. It is understood that the changes, described in the above NDA supplements, have been made.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ms. Lana Chen, R.Ph., Regulatory Project Manager, at (301) 594-2850.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research